X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Exscientia and the University of Oxford announce partnership to develop treatments for Alzheimer's disease

    Exscientia and the University of Oxford announce partnership to develop treatments for Alzheimer’s disease

    Fasenra shows consistent safety and sustained efficacy in long-term Phase III BORA trial in severe eosinophilic asthma

    AstraZeneca and IDT Biologika sign LOI to increase COVID-19 vaccine manufacturing in Europe and secure long-term supply capacity

    Astrazeneca Says Covid-19 Long-Acting Antibody Combination AZD7442 Rapidly Advances Into Phase III Clinical Trials

    Algernon Pharmaceuticals Considers Adding Lung Scarring as an Additional Endpoint for its Phase 2b/3 COVID-19 Study Protocol

    Samsung Biologics, National OncoVenture, and Eutilex obtains IND Approval from FDA

    Samsung Biologics, National OncoVenture, and Eutilex obtains IND Approval from FDA

    Vaxart Announces Positive Preliminary Data from Phase 1 Clinical Trial Evaluating Its Oral COVID-19 Tablet Vaccine Candidate

    Vaxart Announces Positive Preliminary Data from Phase 1 Clinical Trial Evaluating Its Oral COVID-19 Tablet Vaccine Candidate

    Gavi, the Vaccine Alliance, Collaborates with Salesforce to Help Equitably Distribute Two Billion COVID-19 Vaccines by the End of 2021

    GSK and CureVac to develop next generation mRNA COVID-19 vaccines

    Oxford leads first trial investigating dosing with alternating vaccines

    Oxford leads first trial investigating dosing with alternating vaccines

    Moderna Provides Business Update and Announces Three New Development Programs in Infectious Disease Vaccines

    Moderna Provides Business Update and Announces Three New Development Programs in Infectious Disease Vaccines

    Merck, Pfizer get EU nod for Bavencio as bladder cancer maintenance

    Merck, Pfizer get EU nod for Bavencio as bladder cancer maintenance

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Exscientia and the University of Oxford announce partnership to develop treatments for Alzheimer's disease

    Exscientia and the University of Oxford announce partnership to develop treatments for Alzheimer’s disease

    Fasenra shows consistent safety and sustained efficacy in long-term Phase III BORA trial in severe eosinophilic asthma

    AstraZeneca and IDT Biologika sign LOI to increase COVID-19 vaccine manufacturing in Europe and secure long-term supply capacity

    Astrazeneca Says Covid-19 Long-Acting Antibody Combination AZD7442 Rapidly Advances Into Phase III Clinical Trials

    Algernon Pharmaceuticals Considers Adding Lung Scarring as an Additional Endpoint for its Phase 2b/3 COVID-19 Study Protocol

    Samsung Biologics, National OncoVenture, and Eutilex obtains IND Approval from FDA

    Samsung Biologics, National OncoVenture, and Eutilex obtains IND Approval from FDA

    Vaxart Announces Positive Preliminary Data from Phase 1 Clinical Trial Evaluating Its Oral COVID-19 Tablet Vaccine Candidate

    Vaxart Announces Positive Preliminary Data from Phase 1 Clinical Trial Evaluating Its Oral COVID-19 Tablet Vaccine Candidate

    Gavi, the Vaccine Alliance, Collaborates with Salesforce to Help Equitably Distribute Two Billion COVID-19 Vaccines by the End of 2021

    GSK and CureVac to develop next generation mRNA COVID-19 vaccines

    Oxford leads first trial investigating dosing with alternating vaccines

    Oxford leads first trial investigating dosing with alternating vaccines

    Moderna Provides Business Update and Announces Three New Development Programs in Infectious Disease Vaccines

    Moderna Provides Business Update and Announces Three New Development Programs in Infectious Disease Vaccines

    Merck, Pfizer get EU nod for Bavencio as bladder cancer maintenance

    Merck, Pfizer get EU nod for Bavencio as bladder cancer maintenance

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home News

Sepha launches small batch Contract Packaging Service

Content Team by Content Team
14th February 2021
in News, Packaging & Logistic
Sepha launches small batch Contract Packaging Service

We are excited to announce the launch of a contract packaging service to meet rising demand for small batch production. Aimed at the pharmaceutical, nutraceutical and medical device industries, Sepha’s new contract packaging offer is focused on providing cost-effective, low volume runs of blister and medical device packs within short turnarounds. Customers can enjoy timely and flexible production of packs for sampling, testing and research, independent of the availability of larger blister pack lines.

Demand for small batches of pharmaceuticals and medical devices has exploded in recent years, owing to a number of factors, including the rise of personalized medicines and orphan drugs and the industry need to produce small batches economically. This has led to larger pharmaceutical manufacturers and CMOs (Contract Manufacturing Organisations) struggling to accommodate occasional low volumes on their high-speed production lines.

Sepha has introduced the new service in response to this challenge amid increasing calls for support from its larger pharmaceutical customers.

“Customers were looking to us for support with small runs. Some were having to halt 24/7 high speed blister lines to produce a few hundred sample packs. This is not what these lines were designed for and cannot be justified in terms of line clearance and changeover times. Sepha, on the other hand, is ideally placed to take on small runs, as we have all the know-how we have built up over the years with our laboratory-scale EZ Blister packaging projects, consisting of design, manufacture, process parameter optimization and analysis,” explains Paul Smith, Managing Director of Sepha.

He continues: “We believe we have something unique in the marketplace. We have a breadth of experience – spanning pharmaceutical packaging equipment, leak testing, deblistering and packaging design – that is unrivalled in the small volume contract packaging space. In the last 40 years we have partnered hundreds of pharmaceutical companies across the globe and have brought to market over a thousand different blister designs. This new service brings all these strands of our experience together in an exciting offer that will support our customers’ product quality, time to market and pack integrity ambitions.”

Sepha’s contract packaging division will operate from a new packaging facility in Belfast. Housing a range of dedicated blister packaging equipment, it will be able to accommodate the gamut of small-batch packaging projects, from cold-form and thermoform blisters to MAP packs, trays for medical devices, and temperature and humidity controlled packaging.

Sepha will also draw on over 30 years of design experience to offer a holistic blister packaging development service, complete with QA and non-destructive leak testing. Encompassing material selection, tooling design and 3D prototyping, the full-service offering will be particularly attractive to manufacturers looking to test or compare different materials and designs on a pilot scale.

The new contract packaging service is geared towards companies looking to outsource anything from 100 up to 10,000 packs per week, either as one-off runs or longer-term contracts. These might be packs for use in stability studies, multiple formats for patient compliance testing or marketing samples, for example. Multi-national pharmaceutical manufacturers wanting to focus on drug development and outsource the packaging of solid dose tablets, capsules and medical devices will be the main beneficiaries. Sepha is also keen to work with larger CMOs, for whom small or ad-hoc contracts are not always viable.

“We see ourselves working in partnership rather than in competition with large CMOs. We will nurture customers during the low volume, early life cycle stage, then, when a few hundred or thousand blisters becomes a few million, we will work closely with their chosen CMO to ensure a smooth transition into large scale production,” explains Smith.

Whilst the UK & Ireland and Western Europe will be Sepha’s primary target market, the service will be accessible to manufacturers and CMOs across the globe, thanks to strategic partnerships with specialist providers of temperature-controlled logistics with full track & trace.

Previous Post

Exscientia and the University of Oxford announce partnership to develop treatments for Alzheimer's disease

Next Post

Qatar approves emergency use of Modernas COVID-19 vaccine

Related Posts

Johnson & Johnson Prepares to Resume Phase 3 ENSEMBLE Trial of its Janssen COVID-19 Vaccine Candidate in the U.S.
Manufacturing

Evonik strengthens strategic partnership with BioNTech on COVID-19 vaccine

14th February 2021
Qatar approves emergency use of Modernas COVID-19 vaccine
News

Qatar approves emergency use of Modernas COVID-19 vaccine

14th February 2021
Exscientia and the University of Oxford announce partnership to develop treatments for Alzheimer's disease
Drug Development

Exscientia and the University of Oxford announce partnership to develop treatments for Alzheimer’s disease

14th February 2021
PDA to Collaborate with Deloitte and U.S. FDA to Improve the Quality of Compounded Drugs
News

PDA to Collaborate with Deloitte and U.S. FDA to Improve the Quality of Compounded Drugs

14th February 2021
Fasenra shows consistent safety and sustained efficacy in long-term Phase III BORA trial in severe eosinophilic asthma
Drug Development

AstraZeneca and IDT Biologika sign LOI to increase COVID-19 vaccine manufacturing in Europe and secure long-term supply capacity

14th February 2021
Moderna Provides Business Update and Announces Three New Development Programs in Infectious Disease Vaccines
News

Moderna inks agreement to supply of 5 million &10 million doses of Covid-19 vaccine to Taiwan and Colombia governments

14th February 2021
Next Post
Qatar approves emergency use of Modernas COVID-19 vaccine

Qatar approves emergency use of Modernas COVID-19 vaccine

Latest News

Johnson & Johnson Prepares to Resume Phase 3 ENSEMBLE Trial of its Janssen COVID-19 Vaccine Candidate in the U.S.
Manufacturing

Evonik strengthens strategic partnership with BioNTech on COVID-19 vaccine

14th February 2021
Qatar approves emergency use of Modernas COVID-19 vaccine
News

Qatar approves emergency use of Modernas COVID-19 vaccine

14th February 2021
Sepha launches small batch Contract Packaging Service
News

Sepha launches small batch Contract Packaging Service

14th February 2021
Exscientia and the University of Oxford announce partnership to develop treatments for Alzheimer's disease
Drug Development

Exscientia and the University of Oxford announce partnership to develop treatments for Alzheimer’s disease

14th February 2021
PDA to Collaborate with Deloitte and U.S. FDA to Improve the Quality of Compounded Drugs
News

PDA to Collaborate with Deloitte and U.S. FDA to Improve the Quality of Compounded Drugs

14th February 2021
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In